{"id":8304,"date":"2024-05-04T05:28:12","date_gmt":"2024-05-04T05:28:12","guid":{"rendered":"https:\/\/lupus.treefrog.dev\/belimumab-benlysta\/"},"modified":"2024-05-24T13:57:21","modified_gmt":"2024-05-24T13:57:21","slug":"belimumab-benlysta","status":"publish","type":"post","link":"https:\/\/www.lupuscanada.org\/fr\/belimumab-benlysta\/","title":{"rendered":"Le b\u00e9limumab (Benlysta) inscrit en Ontario"},"content":{"rendered":"\n<p><em>Le 29 avril 2024<\/em> \u2013 Lupus Canada a le plaisir d\u2019annoncer que Benlysta (indication de n\u00e9phrite lupique) est inscrit en Ontario \u00e0 compter du 17 avril 2024.<\/p>\n\n<p><strong>R\u00c9CAPITULATIF DES MODIFICATIONS APPORT\u00c9ES AU PRODUIT<\/strong><\/p>\n\n<p>Nous avons le plaisir de vous fournir le Sommaire des modifications apport\u00e9es en avril 2024 \u00e0 l\u2019\u00e9dition no 43 du Formulaire du Programme de m\u00e9dicaments de l\u2019Ontario (PMO) et de l\u2019Index comparatif des m\u00e9dicaments (le \u00ab Formulaire \u00bb), qui entrera en vigueur<strong>  30 avril 2024.  <\/strong>Le document de l\u2019\u00e9dition n\u00b0 43 sera affich\u00e9 sur le site Web du minist\u00e8re  <a href=\"https:\/\/urldefense.com\/v3\/__https:\/www.ontario.ca\/document\/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0__;!!AoaiBx6H!0WECIajh0mLlqyuQFSPDT3Ug7JwlR7J8d0gjSobQvz5cfsmDFuI8AzxHwzT1pZFPpKiVlvNOIINBLm1EEuQzrCSNjilkdX3u%24\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ontario.ca\/document\/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0<\/a>  d\u2019ici le 30 avril 2024.<\/p>\n\n<p>Le minist\u00e8re a mis en ligne un nouveau fichier contenant les modifications apport\u00e9es \u00e0 la liste aux fins de t\u00e9l\u00e9chargement et d\u2019examen (\u00e9dition no 43, Sommaire des modifications \u2013 avril 2024). Il est accessible \u00e0 partir du site Web du minist\u00e8re : <a href=\"https:\/\/urldefense.com\/v3\/__https:\/www.ontario.ca\/document\/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0__;!!AoaiBx6H!0WECIajh0mLlqyuQFSPDT3Ug7JwlR7J8d0gjSobQvz5cfsmDFuI8AzxHwzT1pZFPpKiVlvNOIINBLm1EEuQzrCSNjilkdX3u%24\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ontario.ca\/document\/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0<\/a>.<\/p>\n\n<p>De plus, le Formulaire, les Sommaires des changements et les Bulletins, y compris une version \u00e9lectronique consultable du Formulaire (Formulaire \u00e9lectronique), sont \u00e9galement accessibles \u00e0 partir du site Web du minist\u00e8re : <a href=\"https:\/\/urldefense.com\/v3\/__https:\/www.formulary.health.gov.on.ca\/formulary\/__;!!AoaiBx6H!0WECIajh0mLlqyuQFSPDT3Ug7JwlR7J8d0gjSobQvz5cfsmDFuI8AzxHwzT1pZFPpKiVlvNOIINBLm1EEuQzrCSNjor6Zroc%24\" target=\"_blank\" rel=\"noopener\">https:\/\/www.formulary.health.gov.on.ca\/formulary\/<\/a> \u2013 Le formulaire \u00e9lectronique sera mis \u00e0 jour \u00e0 la date d\u2019entr\u00e9e en vigueur \u2013 le 30 avril 2024.  <\/p>\n\n<p><strong><u>Produits du Programme d\u2019acc\u00e8s exceptionnel (PAE)<\/u><\/strong><\/p>\n\n<p><strong>Benlysta (belimumab) 120 mg\/5 mL, 400 mg\/20 ml Inj Sol (GSK) \u2013 Date d\u2019entr\u00e9e en vigueur : 17 avril 2024<\/strong><\/p>\n\n<p>Pour le traitement des patients atteints de n\u00e9phrite lupique active (LN), sur la base de crit\u00e8res.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 29 avril 2024 \u2013 Lupus Canada a le plaisir d\u2019annoncer que Benlysta (indication de n\u00e9phrite lupique) est inscrit en Ontario \u00e0 compter du 17 avril 2024. R\u00c9CAPITULATIF DES MODIFICATIONS APPORT\u00c9ES AU PRODUIT Nous avons le plaisir de vous fournir le Sommaire des modifications apport\u00e9es en avril 2024 \u00e0 l\u2019\u00e9dition no 43 du Formulaire du [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[92],"tags":[],"topic":[116,113,119,120,117],"audience":[123,122,126,125,124],"class_list":["post-8304","post","type-post","status-publish","format-standard","hentry","category-article-fr","topic-connaissances-medicales","topic-nouvelles-et-evenements","topic-plaidoyer-et-soutien","topic-sensibilisation-et-communaute-fr","topic-vie-et-bien-etre","audience-j-ai-le-lupus","audience-j-ai-recemment-recu-un-diagnostic","audience-je-veux-plaider","audience-professionnel-de-la-sante","audience-une-personne-a-qui-je-tiens-a-le-lupus"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/8304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/comments?post=8304"}],"version-history":[{"count":0,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/8304\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/media?parent=8304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/categories?post=8304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/tags?post=8304"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/topic?post=8304"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/audience?post=8304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}